Reviewed by The Peptide Dispatch Editorial Team · Last reviewed July 6, 2026
Pinealon (PIN) is a cognitive peptide, at the approved (russia) stage in the published literature. Pinealon (Glu-Asp-Arg, also known as EDR) is a synthetic tripeptide bioregulator developed at the Saint Petersburg Institute of Bioregulation and Gerontology by Professor Vladimir Khavinson. It specifically targets the central nervous system and pineal gland. Research has shown that Pinealon can modulate melatonin synthesis, enhance antioxidant defenses in neural tissue, and protect neurons from age-related damage.
Pinealon (Glu-Asp-Arg, also known as EDR) is a synthetic tripeptide bioregulator developed at the Saint Petersburg Institute of Bioregulation and Gerontology by Professor Vladimir Khavinson. It specifically targets the central nervous system and pineal gland. Research has shown that Pinealon can modulate melatonin synthesis, enhance antioxidant defenses in neural tissue, and protect neurons from age-related damage.
| Research Status | Approved (Russia) |
|---|---|
| Half-Life | Short (tripeptide, rapid absorption) |
| Administration | Oral, Sublingual |
| Doses Reported in Published Studies | 10-20 mcg oral |
| Molecular Weight | 404.4 Da |
| Molecular Formula | C15H25N5O8 |
Pinealon modulates gene expression in neurons and pinealocytes by penetrating cell membranes and interacting with DNA regulatory regions. It promotes melatonin synthesis in the pineal gland, enhances antioxidant defense in neural tissue, and supports neurotransmitter balance.
Pinealon (Glu-Asp-Arg, also known as EDR) is a synthetic tripeptide bioregulator developed at the Saint Petersburg Institute of Bioregulation and Gerontology by Professor Vladimir Khavinson. It specifically targets the central nervous system and pineal gland. Research has shown that Pinealon can modulate melatonin…
Pinealon modulates gene expression in neurons and pinealocytes by penetrating cell membranes and interacting with DNA regulatory regions. It promotes melatonin synthesis in the pineal gland, enhances antioxidant defense in neural tissue, and supports neurotransmitter balance.
Pinealon is at the following stage in the published literature: Approved (Russia). All information is for research and educational purposes only.
Reported half-life: Short (tripeptide, rapid absorption).
Reported administration route in the literature: Oral, Sublingual. This is not a recommendation for human use.
Educational content, not medical advice. Effects described are drawn from cited research in study subjects.